VPRIV® (velaglucerase alfa) for injection is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.

Roxanne’s Story

AGE: 50s

Age at Diagnosis: 42

Location: Texas, US

For Roxanne, a dedicated caregiver and community servant, her diagnosis with type 1 Gaucher disease (GD1) was unexpected and life-changing. Her story is one of determination and positivity, as she navigated uncertainty, treatment, and advocacy while continuing to focus on her family and newfound purpose.

0:00

listen to Roxanne’s story

Discover Roxanne’s story below, or click play to hear
it in her own words.

Play Icon
Roxanne’s Family

A Life of Service and an Unexpected Diagnosis

“I loved helping everyone from the young tots to the young-at-heart seniors. I have also been the rock of my family, for not only my kids but for my mom and my siblings as well.”

Roxanne has always been dedicated to serving others. Throughout her career as a secretary in churches and schools, she has thrived on helping and supporting people of all ages. She is also the cornerstone of her family, offering unwavering care to her children, siblings, and mother. Roxanne considers her nurturing spirit to be her calling and has embraced it wholeheartedly.

Her journey with GD1 began unexpectedly when her sister struggled with fertility issues. Routine tests revealed irregularities in her sister’s liver and spleen function, leading to a referral to a hematologist. Roxanne provided emotional support, and the diagnosis of GD1 was both a relief and a source of confusion. It wasn’t cancer, but it was unfamiliar and potentially serious. Searching online for answers yielded little information, leaving them feeling lost and overwhelmed.

Finding Answers and Facing Fears

“I was in shock. I had tried to brace myself, but the diagnosis just took the wind out of my sails. I was so grateful I had gone with my sister to her appointments. I knew what I was facing.”

Determined to find the best care, Roxanne accompanied her sister to a geneticist, only to be disappointed when the specialist admitted to knowing little about GD1. Their persistence led them to a pediatric geneticist who explained the genetic nature of the disease, its impact on various organs, and available treatments.

watch Love, Me Video

Roxanne Love, Me Video

The geneticist recommended that Roxanne and other family members get tested for GD1. Initially dismissing the idea, Roxanne reconsidered as she reflected on her persistent bone pain, fatigue, and other unexplained symptoms. After attributing these issues to stress for years, she underwent genetic testing in February 2017, and the GD1 diagnosis was confirmed. For Roxanne, this news was overwhelming and she was frightened about the future.

Advocating for Awareness and Supporting the Community

“I’m part of Gaucher Community Alliance. It’s been great. Meeting other people and hearing their journeys and knowing that there are other people with the same aches and pains. Getting to get together…because even your family doesn’t understand sometimes.”

Adjusting to life with GD1 was challenging. Roxanne faced hurdles navigating the healthcare system, from changing infusion centers to dealing with complex insurance processes. Despite these struggles, she found strength in the GD1 community through organizations like the National Gaucher Foundation and the Gaucher Community Alliance. Initially feeling out of place as one of the few Hispanic members, she discovered invaluable resources and built meaningful connections.

In 2019, Roxanne retired from her professional career, an emotionally difficult transition as she grappled with losing a significant part of her identity. However, her diagnosis fueled a new passion—advocating for greater awareness and research for GD1. The condition became even more personal when her grandson was also diagnosed with GD1, reinforcing her resolve to fight for future generations.

VPRIV Patient Ambassador Roxanne and her Grandson

Today, Roxanne educates others about GD1 and encourages newly diagnosed patients to advocate for themselves. She emphasizes the importance of seeking information, support, and advocating for treatment. Her message is clear: patients should never give up. Roxanne continues to find purpose in her role as a caregiver, advocate, and loving grandmother.

VPRIV Patient Ambassador Roxanne

Living with Purpose and Hope

“I believe patients should never give up. I’m fighting for future generations, including my grandson. I want to be with him all the way.”

Despite the challenges posed by GD1, Roxanne remains focused on what she holds most dear—her family and community. Her treatments are now a routine part of her life, and she continues to stay involved in her daily activities. She continues to provide support to her loved ones and looks forward to spending precious time with her grandson.

Reflecting on her journey, Roxanne acknowledges the emotional and physical difficulties she has faced but remains optimistic about the future. She believes that raising awareness and advocating for improved patient care can make a meaningful difference. Her message to others is one of hope and empowerment: with determination, support, and the right information, life with GD1 can be managed, and dreams can still be pursued.

important safety information <

Life-threatening hypersensitivity reactions, including anaphylaxis may occur with VPRIV treatment. This reaction may occur early in treatment or after many doses. Seek immediate help if you experience wheezing, shortness of breath, trouble breathing, itching, hives, rapid heartbeat, swelling of the tongue or throat.

important safety information <

Life-threatening hypersensitivity reactions, including anaphylaxis may occur with VPRIV treatment. This reaction may occur early in treatment or after many doses. Seek immediate help if you experience wheezing, shortness of breath, trouble breathing, itching, hives, rapid heartbeat, swelling of the tongue or throat. VPRIV should be administered under the supervision of a healthcare professional. Appropriate medical support should be available when VPRIV is administered.

Hypersensitivity reactions were the most commonly observed side effects in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of hypersensitivity reactions were: headache, dizziness, low blood pressure, high blood pressure, nausea, tiredness/weakness, and fever. Hypersensitivity reactions in the clinical trials include any event considered related to and occurring within up to 24 hours of VPRIV infusion, including one case of anaphylaxis. Generally the reactions were mild and, in patients not previously treated, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. After the drug was approved, additional hypersensitivity reactions of chest discomfort, difficulty breathing, itching and vomiting have been reported. In some cases, vomiting can be serious and require hospitalization and/or stopping the medication.

If anaphylactic or other acute reactions occur, seek immediate medical care. Your healthcare provider will immediately discontinue the infusion of VPRIV and initiate the appropriate medical treatment. A hypersensitivity reaction should be treated based on the severity of the reaction. Your healthcare provider may manage a reaction by slowing the infusion rate or treating with medicine such as antihistamines, fever-reducing agents and/or corticosteroids or possibly stopping the medication and then restarting with a longer infusion time. For patients who have had symptoms of hypersensitivity reaction to enzyme replacement therapy, the doctor may consider treating the patient with antihistamines and/or corticosteroids before an infusion to help prevent such a reaction from happening.

The most commonly reported side effects during clinical studies (in ≥10% of patients) were hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, increased time it takes for blood to clot, tiredness/weakness, and fever. In clinical studies, the overall frequency of side effects was generally higher in the patients not previously treated with ERT than in the patients who switched from imiglucerase to VPRIV.

Talk to your doctor if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

The safety and efficacy profiles were similar in pediatric (ages 4 to 17) and adult patients. The safety of VPRIV has not been established in patients under 4 years of age. Side effects more commonly seen in pediatric patients compared to adult patients include (>10% difference): rash, increased time it takes for blood to clot, and fever.

The side effect profile in elderly patients was generally similar to that seen in pediatric and other adult patients. In general, dose selection for an elderly patient should be approached cautiously, considering other existing medical conditions.

As with all therapeutic proteins, there is a potential for developing antibodies to VPRIV. In clinical studies, 1 of 54 (2%) patients who had not previously been treated with ERT, who were then treated with VPRIV, developed antibodies. One additional patient developed antibodies to VPRIV during an extension study. It is unknown if having antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies to VPRIV.

For additional safety information, please click here for Full Prescribing Information including WARNING for Risk of Anaphylaxis, and discuss with your doctor
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, contact Takeda at 1-877-TAKEDA-7 (1-877-825-3327), or by email at medinfous@takeda.com